Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

Y0001434

Montelukast sodium

European Pharmacopoeia (EP) Reference Standard

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C35H35ClNO3S·Na
Numero CAS:
151767-02-1
Peso molecolare:
608.17
Codice UNSPSC:
41116107
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

montelukast

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

InChI

1S/C35H36ClNO3S.Na/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);/q;+1/p-1/b15-10+;/t32-;/m1./s1
LBFBRXGCXUHRJY-HKHDRNBDSA-M

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Montelukast sodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Y0001433

Montelukast racemate, European Pharmacopoeia (EP) Reference Standard

Y0001435

Montelukast for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001436

Montelukast dicyclohexylamine, European Pharmacopoeia (EP) Reference Standard

1446859

Montelukast sodium, United States Pharmacopeia (USP) Reference Standard

1446848

Montelukast racemate, United States Pharmacopeia (USP) Reference Standard

1446815

Montelukast dicyclohexylamine, United States Pharmacopeia (USP) Reference Standard

1446837

Montelukast for peak identification, United States Pharmacopeia (USP) Reference Standard

BP1147

Montelukast dicyclohexylamine, British Pharmacopoeia (BP) Reference Standard

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 5

1 of 5

USP

USP

1446848

Montelukast racemate

Zafirlukast ≥98% (HPLC)

Sigma-Aldrich

Z4152

Zafirlukast

trans-2-Phenylcyclopropylamine hydrochloride

Sigma-Aldrich

P8511

trans-2-Phenylcyclopropylamine hydrochloride

(S)-(+)-Mephenytoin solid, ≥98% (HPLC)

Sigma-Aldrich

UC175

(S)-(+)-Mephenytoin

Dexamethasone-Water Soluble suitable for cell culture, BioReagent

Sigma-Aldrich

D2915

Dexamethasone-Water Soluble

Genyo Ikeda et al.
American journal of respiratory cell and molecular biology, 50(1), 18-29 (2013-08-14)
The incidence of overlapping bronchial asthma and chronic obstructive pulmonary disease has increased in recent years. Cysteinyl leukotrienes (CysLTs) play an important role in asthma, and the type 1 CysLT receptor (CysLT1R) is expressed by many inflammatory cells. We evaluated
Timothy S Chang et al.
The Journal of allergy and clinical immunology, 133(2), 363-369 (2013-10-22)
Childhood asthma clusters, or subclasses, have been developed by computational methods without evaluation of clinical utility. To replicate and determine whether childhood asthma clusters previously identified computationally in the Severe Asthma Research Program (SARP) are associated with treatment responses in
Stefano Fogli et al.
Pharmacological research, 76, 149-156 (2013-08-21)
Microparticles (MPs) are membrane fragments that may play a role in the pathogenesis of chronic respiratory diseases. We aimed to investigate whether human monocytes/macrophage-derived MPs could induce a pro-inflammatory phenotype in human bronchial smooth muscle cells (BSMC) and the effect
Yves Pacheco et al.
The Journal of asthma : official journal of the Association for the Care of Asthma, 51(1), 1-17 (2013-07-10)
Rhinitis and other specific triggers or co-morbidities (tobacco exposure, excess weight, aspirin sensitivity or heredity factors) are frequently associated with uncontrolled asthma. Asthma associated with these exacerbating factors appears to be related to an increase in leukotriene-mediated inflammation. We reviewed
Nathan Rabinovitch et al.
The Journal of allergy and clinical immunology, 133(2), 350-356 (2013-10-03)
Predictors of improvement in asthma control and lung function to step 3 therapy in children with persistent asthma have not been identified despite reported heterogeneity in responsiveness. We sought to evaluate potential predictors of asthma control and lung function responsiveness
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.